RE:RE:RE:RE:RE:9 more sites
enriquesuave wrote: I just checked and see that Endocyte buyout happened in Oct. 2018 and the drug approval was 3.5 years later in March of 2022. If we get AA, then a good chance we get bought out with an approved drug and while 3 PH1 trials are in place, GBM, NSCLC and COVID.. $2.1 Billion will be cheap. IMHO
Yep....& that drug approval was for only one indication. As you inferred, our single drug/ACT has the realistic potential to cover multiple indications, which should add Billions to that $2.1 Billion price tag. I also believe the market doesn't have a clue (including some Big Pharmas) as to the kind of ground-breaking potential TLT holds in its ACT/IP....an ACT that can be more easily modified/adapted to improve upon its own performance unlike other drugs/technologies.
During these difficult times, it's always nice to remember that all good science has its wonders, & I'm hopeful many will get to realize the bulk of its worth. Life (like drug development) likes to throw a few curves now & then, but no matter what curve or calamity is thrown in my direction, my level of contentment shall not wane as hope is finally approaching reality & my family/descendants may soon be given that new lease on quality of life....hats off to Theralase.
Helen Keller quote: "Everything has it wonders, even darkness and silence...and I learn, whatever state I may be in, therein to be content."